Terremoto named Mirati vet Christensen as CEO, as the start-up looks to execute on its next phase as a well-funded company. The leadership move follows the kind of commercial and operational ramp common to preclinical-to-clinic transitions, with a focus on bringing differentiated assets into development and partnership-building. While financial and program specifics were not detailed in the item, the appointment signals continuity in experienced oncology product leadership within a startup environment that has recently gained attention from investors for early-stage direction.